BJ
MYGN icon

BlackRock Japan’s Myriad Genetics MYGN Stock Holding History

BlackRock Japan’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$6K Sell
378
-1,071
-74% -$19.4K ﹤0.01% 1251
2016
Q3 		$30K Sell
1,449
-63
-4% -$1.6K ﹤0.01% 1056
2016
Q2 		$46K Buy
1,512
+48
+3% +$1.67K ﹤0.01% 1007
2016
Q1 		$55K Buy
1,464
+14
+1% +$528 ﹤0.01% 1014
2015
Q4 		$63K Buy
1,450
+617
+74% +$26.1K ﹤0.01% 992
2015
Q3 		$31K Buy
833
+37
+5% +$1.31K ﹤0.01% 1045
2015
Q2 		$27K Buy
+796
New +$27.1K ﹤0.01% 1152
2014
Q3 		– Sell
-1,863
Closed -$73K – 1288
2014
Q2 		$73K Buy
1,863
+1,011
+119% +$37.6K ﹤0.01% 988
2014
Q1 		$29K Sell
852
-14,645
-95% -$454K ﹤0.01% 1234
2013
Q4 		$325K Buy
15,497
+1,833
+13% +$46.4K ﹤0.01% 824
2013
Q3 		$321K Buy
13,664
+1,602
+13% +$45.5K ﹤0.01% 817
2013
Q2 		$324K Buy
+12,062
New +$350K ﹤0.01% 792

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock Japan's MYGN Position: Q4 2016 in Review

BlackRock Japan reduced its Myriad Genetics (MYGN) stake by 74% in Q4 2016, selling an estimated $19.4K and leaving 378 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1251.

BlackRock Japan first reported a position in MYGN in Q2 2013 and has held it in 12 quarters since. The position peaked at $325K in Q4 2013. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • BlackRock Japan held 378 shares of Myriad Genetics worth $6K as of Q4 2016.
  • BlackRock Japan sold 1,071 Myriad Genetics shares in Q4 2016, an estimated $19.4K.
  • Myriad Genetics made up ﹤0.01% of BlackRock Japan's portfolio in Q4 2016, its #1251 holding.
  • BlackRock Japan first reported a position in Myriad Genetics in Q2 2013 and has held it in 12 quarters since.
  • BlackRock Japan's Myriad Genetics position peaked at $325K in Q4 2013.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on BlackRock Japan's 13F filing for Q4 2016, filed 10 Feb 2017.